Flurizan Ineffective for Prostate Cancer
Myriad Genetics, Inc. (NASDAQ: MYGN) announced today the results of its multi-center, double-blind, placebo-controlled human clinical trial of MPC-7869 (Flurizan™ R-flurbiprofen) in prostate cancer.
The drug had no side effects but nor did it have any positive effect on the patients’ prostate “ancer. The company will not pursue Flurizan™ further for cancer but will continue to look for other uses, primarily for Alzheimer’s disease.
(full story…)